Quick Answer
Citius Pharmaceuticals, Inc. reported Operating Income of -$38.53 million for fiscal year 2025.
Citius Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$38.53M | +8.3% |
| 2024 | -$42.00M | -14.3% |
| 2023 | -$36.73M | -10.3% |
| 2022 | -$33.32M | -41.6% |
| 2021 | -$23.53M | -32.9% |
| 2020 | -$17.71M | -13.5% |
| 2019 | -$15.60M | -13.1% |
| 2018 | -$13.79M | -38.1% |
| 2017 | -$9.99M | -34.1% |
| 2016 | -$7.45M | -130.6% |
| 2015 | -$3.23M | -394.0% |
| 2014 | -$653.8K | +44.7% |
| 2013 | -$1.18M | -4105.6% |
| 2013 | -$28.1K | -43.3% |
| 2012 | -$19.6K | +23.5% |
| 2011 | -$25.6K | -65.4% |
| 2010 | -$15.5K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$9.02M | +10.2% | -2.6% |
| June 30, 2025 | -$8.79M | +17.4% | +22.0% |
| March 31, 2025 | -$11.26M | -2.6% | -12.2% |
| December 31, 2024 | -$10.04M | -7.5% | +5.6% |
| June 30, 2024 | -$10.63M | -22.6% | +3.1% |
| March 31, 2024 | -$10.97M | -2.7% | -17.4% |
| December 31, 2023 | -$9.34M | -28.8% | -7.7% |
| June 30, 2023 | -$8.67M | +2.7% | +18.8% |
- Citius Pharmaceuticals, Inc. showed an increase of +8.3% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, Citius Pharmaceuticals, Inc.’s operating income has declined by 248452.3% (from -$15.5 thousand to -$38.53 million).
- The most recent figure is from Citius Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: